The findings demonstrate that AEOL reduces mitochondrial ROS production, decreases myocardial infarct size, and improves cardiac function through NRF2-mediated upregulation of DWORF, which enhances SERCA2a activity by disrupting the phospholamban-SERCA2a interaction. This evidence concerns the gene NFE2L2 and myocardial infarction.